On January 23, GSK announced that the National Medical Products Administration (NMPA) had approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol inhalation powder, FF/UMEC/VI) for the maintenance treatment of adult patients with asthma.
This approval expands the product beyond its original indication for chronic obstructive pulmonary disease (COPD) and makes FF/UMEC/VI the first and only single-inhaler triple therapy (SITT) in China for the maintenance treatment of both asthma and COPD.
The approval was mainly based on GSK’s CAPTAIN clinical study. The study showed that, in patients inadequately controlled on inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) therapy, the additional bronchodilation provided by FF/UMEC/VI significantly improved lung function compared with the dual therapy FF/VI.
FF/UMEC/VI is a once-daily single-inhaler triple therapy administered through a single inhalation. It contains three components: the inhaled corticosteroid (ICS) fluticasone furoate (FF), the long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC), and the long-acting beta2-agonist (LABA) vilanterol (VI), delivered via GSK’s proprietary Ellipta dry powder inhaler.
FF/UMEC/VI has been launched in multiple countries and regions including China, the United States, Europe, and Japan. Approved strengths in China include 100/62.5/25 μg for asthma and COPD, and 200/62.5/25 μg for asthma.
Since launch, sales of the product have surged, reaching USD 3.452 billion in 2024 and USD 2.942 billion in the first three quarters of 2025.